{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Childhood+Neoplasm&page=43", "query": { "condition": "Malignant Childhood Neoplasm", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 2041, "total_pages": 205, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Childhood+Neoplasm&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Childhood+Neoplasm&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T21:58:19.294Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02910700", "title": "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2016-12-09", "completion_date": "2027-12-08", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02910700" }, { "nct_id": "NCT00045292", "title": "Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "acyclovir", "type": "DRUG" }, { "name": "acyclovir sodium", "type": "DRUG" }, { "name": "valacyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": "2002-04", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 6, "location_summary": "Duarte, California • Stanford, California • Omaha, Nebraska + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045292" }, { "nct_id": "NCT03565367", "title": "Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Central Nervous System Neoplasm", "Metastatic Malignant Neoplasm in the Central Nervous System" ], "interventions": [ { "name": "Gadolinium", "type": "OTHER" }, { "name": "Hyperpolarized Carbon C 13 Pyruvate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Daniel M. Spielman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-11-06", "completion_date": "2019-06-20", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03565367" }, { "nct_id": "NCT02414269", "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Pleural Disease", "Mesothelioma", "Metastases", "Lung Cancer", "Breast Cancer" ], "interventions": [ { "name": "iCasp9M28z T cell infusions", "type": "GENETIC" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2015-05", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02414269" }, { "nct_id": "NCT04266886", "title": "Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Female Reproductive System Neoplasm", "Metastatic Cervical Cancer" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Hypnotherapy", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 152, "start_date": "2018-09-11", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04266886" }, { "nct_id": "NCT00030108", "title": "Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Leukemia", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 30, "start_date": "2001-11", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030108" }, { "nct_id": "NCT03543852", "title": "SurvivorLink: Scalability of an Electronic Personal Health Record", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Childhood Cancer" ], "interventions": [ { "name": "SurvivorLink", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 580, "start_date": "2021-06-14", "completion_date": "2024-12-25", "has_results": false, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03543852" }, { "nct_id": "NCT06265285", "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Esophageal Squamous Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Esophageal Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Hepatocellular Carcinoma", "Locally Advanced Urothelial Carcinoma", "Lung Non-Small Cell Carcinoma", "Malignant Solid Neoplasm", "Metastatic Colorectal Carcinoma", "Metastatic Cutaneous Melanoma", "Metastatic Esophageal Squamous Cell Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Esophageal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Unresectable Cutaneous Melanoma", "Unresectable Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Home Health Encounter", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-04-30", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06265285" }, { "nct_id": "NCT02750215", "title": "A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Non-small Cell Neoplasm of Lung Stage IV" ], "interventions": [ { "name": "Capmatinib (INC280)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-05", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02750215" }, { "nct_id": "NCT00450736", "title": "Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Malignant Fibrous Histiocytoma of Bone", "Sarcoma" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2004-03", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-10-17T21:58:19.294Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450736" } ] }